AR067047A1 - ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. - Google Patents

ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION.

Info

Publication number
AR067047A1
AR067047A1 ARP080102596A ARP080102596A AR067047A1 AR 067047 A1 AR067047 A1 AR 067047A1 AR P080102596 A ARP080102596 A AR P080102596A AR P080102596 A ARP080102596 A AR P080102596A AR 067047 A1 AR067047 A1 AR 067047A1
Authority
AR
Argentina
Prior art keywords
injection
acetaminofen
sodium bicarbonate
added
acetaminophen
Prior art date
Application number
ARP080102596A
Other languages
Spanish (es)
Inventor
Lloret Sergio Perez
Pena Agnes Fernandez
Original Assignee
Combino Pharm Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combino Pharm Sl filed Critical Combino Pharm Sl
Publication of AR067047A1 publication Critical patent/AR067047A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1:Una formulacion acuosa estable de acetaminofén para inyeccion, caracterizada porque comprende: a) entre aproximadamente 200,0 mg y aproximadamente 1.400,0 mg de acetaminofén; b) entre aproximadamente 200,0 mg y aproximadamente 10.000,0 mg de manitol para inyeccion; c) entre aproximadamente 0,0 mg y aproximadamente 30,0 mg de fosfato de sodio monobásico; d) entre aproximadamente 0,0 mg y aproximadamente 300,0 mg de povidona; e) entre aproximadamente 2,0 mg y aproximadamente 100,0 mg de L-cisteína, f) una cantidad suficiente de bicarbonato de sodio que se agrega durante la síntesis para ajustar el pH por encima de 8,0; g) luego, se agrega una cantidad suficiente de ácido cítrico luego del bicarbonato de sodio con el objetivo de disminuir el pH hasta entre aproximadamente 6,0 y aproximadamente 40; y h) un volumen de agua para inyeccion hasta un volumen de aproximadamente 100 mL; en donde el mencionado ácido cítrico se agrega luego de la adicion del mencionado bicarbonato de sodio.Claim 1: A stable aqueous formulation of acetaminophen for injection, characterized in that it comprises: a) between about 200.0 mg and about 1,400.0 mg of acetaminophen; b) between about 200.0 mg and about 10,000.0 mg of mannitol for injection; c) between about 0.0 mg and about 30.0 mg of monobasic sodium phosphate; d) between about 0.0 mg and about 300.0 mg of povidone; e) between about 2.0 mg and about 100.0 mg of L-cysteine, f) a sufficient amount of sodium bicarbonate that is added during the synthesis to adjust the pH above 8.0; g) then, a sufficient amount of citric acid is added after sodium bicarbonate in order to lower the pH to between about 6.0 and about 40; and h) a volume of water for injection to a volume of approximately 100 mL; wherein said citric acid is added after the addition of said sodium bicarbonate.

ARP080102596A 2007-06-18 2008-06-18 ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. AR067047A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92919307P 2007-06-18 2007-06-18

Publications (1)

Publication Number Publication Date
AR067047A1 true AR067047A1 (en) 2009-09-30

Family

ID=40785551

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102596A AR067047A1 (en) 2007-06-18 2008-06-18 ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION.

Country Status (2)

Country Link
AR (1) AR067047A1 (en)
WO (1) WO2009081283A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2464332B1 (en) 2009-08-13 2016-03-02 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
US8404748B2 (en) 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
EP2672955A1 (en) 2011-02-10 2013-12-18 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
ES2414557B1 (en) * 2012-01-16 2014-06-10 Novocat Farma, S.A. Aqueous composition of paracetamol for injection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751875B1 (en) * 1996-08-05 1998-12-24 Scr Newpharm NOVEL STABLE LIQUID FORMULATIONS BASED ON PARACETAMOL AND THEIR METHOD OF PREPARATION
FR2809619B1 (en) * 2000-06-06 2004-09-24 Pharmatop NOVEL AQUEOUS FORMULATIONS OF OXIDATION-SENSITIVE ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING THEM
EP1469885A1 (en) * 2001-12-18 2004-10-27 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Parenteral composition of paracetamol
FR2851164B1 (en) * 2003-02-14 2005-04-22 Xuan Tho Nguyen INFLATABLE LIQUID FORMULATION OF PARACETAMOL
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions

Also Published As

Publication number Publication date
WO2009081283A3 (en) 2009-08-20
WO2009081283A2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
CY1122516T1 (en) READY-TO-USE FORMULATIONS OF KETOROLAK
AR074347A1 (en) SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH DEFICIENT WATER SOLUBILITY AT LOW PH AND ITS METHODS OF USE
AR083034A1 (en) STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH A WATERY FORMULATION WITH SODIUM CHLORIDE AT A WEAK ACID pH NEUTRAL
CL2017002488A1 (en) Stable pharmaceutical formulation for intrathecal administration comprising an arylsulfatase (loop) protein, salt and a polysorbate surfactant and / or a buffering agent, and which may also contain a stabilizing agent; container comprising said formulation; use to treat metachromatic leukodystrophy (mld) disease. (divisional application 3654-2012)
UY27320A1 (en) NEW PHARMACEUTICAL COMPOSITIONS
PE20071310A1 (en) LIQUID PHENYLEPHRINE FORMULATIONS
PE20070437A1 (en) AQUEOUS FORMULATION hFSH
NZ621448A (en) Highly concentrated pharmaceutical formulations comprising anti - cd20 antibody
RS52566B (en) Liquid lh formulations
PE20050822A1 (en) FLORPHENICOL DERIVATIVES WITH BETTER SOLUBILITY IN WATER
PE20131324A1 (en) SUBCUTANEOUS FORMULATION OF ANTI-HER2 ANTIBODY
DK1317419T3 (en) Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents
ES2720954T3 (en) Statin Stabilized Formulations
PE20120788A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS
EA201170543A1 (en) PHARMACEUTICAL LIQUID COMPOSITION CONTAINING PARACETAMOL
AR068598A1 (en) FLUORIDE ORAL FOAM CARE COMPOSITION FORMING FOAM
AR067048A1 (en) ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION.
AR074541A1 (en) NATURAL SILVER DISINFECTANT COMPOSITIONS
AR067047A1 (en) ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION.
AR034370A1 (en) A CILOSTAZOL WATERPROOF PHARMACEUTICAL PREPARATION FOR PARENTERAL USE
PE20011223A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING PEMETREXED AND AN ANTIOXIDANT SUCH AS MONOTHIOGLYCEROL, L-CYSTEINE AND THIOGLICOLIC ACID
SE9903831D0 (en) Formulation of substituted benzimidazoles
MX2007009312A (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts.
EA200300406A1 (en) PHARMACEUTICAL COMPOSITION OF DRUNEDARON FOR PARENTERAL INTRODUCTION
PE20130374A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING IBUPROFEN

Legal Events

Date Code Title Description
FB Suspension of granting procedure